This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox Reserved 1369
From Proteopedia
| Line 7: | Line 7: | ||
EGFR plays a role in the metastasization and development of carcinomas, because it contributes to growth in epithelial tissue.The irreversible inhibition EGFR by Mig-6 will, in people with cancer, prevent the cancer from growing and progressing further. Therefore, Mig-6 regulates the activities of EGFR, so that growth does not get out of control. | EGFR plays a role in the metastasization and development of carcinomas, because it contributes to growth in epithelial tissue.The irreversible inhibition EGFR by Mig-6 will, in people with cancer, prevent the cancer from growing and progressing further. Therefore, Mig-6 regulates the activities of EGFR, so that growth does not get out of control. | ||
== Disease == | == Disease == | ||
| - | The Mig-6/EGFR protein complex has great importance to the prevention and suppression of epithelial tumors. Since EGFR promotes epithelial growth, and therefore the growth of epithelial cancers when they occur, the Mig-6/EGFR complex is essentially a tumor suppressing complex, because Mig-6 inhibits the function of EGFR | + | The Mig-6/EGFR protein complex has great importance to the prevention and suppression of epithelial tumors. Since EGFR promotes epithelial growth, and therefore the growth of epithelial cancers when they occur, the Mig-6/EGFR complex is essentially a tumor suppressing complex, because Mig-6 inhibits the function of EGFR. |
== Relevance == | == Relevance == | ||
| - | Mig-6 is a feedback inhibitor that binds, inhibits, and drives internalization of ErbB-family receptors. Mig-6 inactivates the EGFR and thus is critical in better understanding human | + | Mig-6 is a feedback inhibitor that binds, inhibits, and drives internalization of ErbB-family receptors. Mig-6 inactivates the EGFR and thus is critical in better understanding human cancers. |
Somatic mutations in the EGFR kinase domain have been shown to drive lung adenocarcinoma, a specific type of lung cancer. Mig-6 is a target for phosphorylation by mutant EGFR’s and is a promising tumor suppressor for mutant-driven lung adenocarcinoma. During a research study, lung tumor formation progressed faster in mice lacking Mig-62. Interaction between Mig-6 and EGFR, stabilizes EGFR, inhibiting mutant EGFR, and preventing or delaying further growth of mutant EGFR-driven tumors. | Somatic mutations in the EGFR kinase domain have been shown to drive lung adenocarcinoma, a specific type of lung cancer. Mig-6 is a target for phosphorylation by mutant EGFR’s and is a promising tumor suppressor for mutant-driven lung adenocarcinoma. During a research study, lung tumor formation progressed faster in mice lacking Mig-62. Interaction between Mig-6 and EGFR, stabilizes EGFR, inhibiting mutant EGFR, and preventing or delaying further growth of mutant EGFR-driven tumors. | ||
| Line 20: | Line 20: | ||
Global Stoichiometry: Hetero 2-mer - AB2 | Global Stoichiometry: Hetero 2-mer - AB2 | ||
| - | The domain structure of Mig6 includes an N-terminal CRIB domain, a motif that mediates association with the Rho-family GTPase Cdc42 and a C-terminal ErbB-binding region, which is necessary and sufficient for binding and inhibition of EGFR7. | + | The domain structure of Mig6 includes an N-terminal CRIB domain, a motif that mediates association with the Rho-family GTPase Cdc42 and a C-terminal ErbB-binding region, which is necessary and sufficient for binding and inhibition of EGFR7. |
| - | + | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
| - | + | 1. Park, E., Kim, N., Ficarro, S. B., Zhang, Y., Lee, B. I., Cho, A., . . . Eck, M. J. (2015, August 17). Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Retrieved February 21, 2018, from https://www.nature.com/articles/nsmb.3074 | |
| - | 3. https://www.ncbi.nlm.nih.gov/pubmed/25735773 | + | 2. Park, E., Kim, N., Ficarro, S., Zhang, Y., Lee, B., Cho, A., . . . Eck, M. (n.d.). Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Retrieved February 21, 2018, from http://www.rcsb.org/structure/4ZJV |
| - | 4. https://www.ncbi.nlm.nih.gov/pubmed/16377102 | + | 3. Maity, T. K., Venugopalan, A., Linnoila, I., Cultraro, C. M., Giannakou, A., Nemati, R., . . . Guha, U. (2015, May). Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. Retrieved February 21, 2018, from https://www.ncbi.nlm.nih.gov/pubmed/25735773 |
| - | 5. https://www.ebi.ac.uk/pdbe/entry/pdb/4zjv/citations | + | 4. Normanno, N., De, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., . . . Salomon, D. S. (2006, January 17). Epidermal growth factor receptor (EGFR) signaling in cancer. Retrieved February 21, 2018, from https://www.ncbi.nlm.nih.gov/pubmed/16377102 |
| + | 5. Europe, P. D. (1970, January 01). Structure analysis. Retrieved February 21, 2018, from https://www.ebi.ac.uk/pdbe/entry/pdb/4zjv/citations | ||
Revision as of 21:35, 21 February 2018
| This Sandbox is Reserved from January through July 31, 2018 for use in the course HLSC322: Principles of Genetics and Genomics taught by Genevieve Houston-Ludlam at the University of Maryland, College Park, USA. This reservation includes Sandbox Reserved 1311 through Sandbox Reserved 1430. |
To get started:
More help: Help:Editing |
Your Heading Here (maybe something like 'Structure')
| |||||||||||
References
1. Park, E., Kim, N., Ficarro, S. B., Zhang, Y., Lee, B. I., Cho, A., . . . Eck, M. J. (2015, August 17). Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Retrieved February 21, 2018, from https://www.nature.com/articles/nsmb.3074 2. Park, E., Kim, N., Ficarro, S., Zhang, Y., Lee, B., Cho, A., . . . Eck, M. (n.d.). Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Retrieved February 21, 2018, from http://www.rcsb.org/structure/4ZJV 3. Maity, T. K., Venugopalan, A., Linnoila, I., Cultraro, C. M., Giannakou, A., Nemati, R., . . . Guha, U. (2015, May). Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma. Retrieved February 21, 2018, from https://www.ncbi.nlm.nih.gov/pubmed/25735773 4. Normanno, N., De, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., . . . Salomon, D. S. (2006, January 17). Epidermal growth factor receptor (EGFR) signaling in cancer. Retrieved February 21, 2018, from https://www.ncbi.nlm.nih.gov/pubmed/16377102 5. Europe, P. D. (1970, January 01). Structure analysis. Retrieved February 21, 2018, from https://www.ebi.ac.uk/pdbe/entry/pdb/4zjv/citations
